Tecartus
The medicinal product has been authorised by the European Commission (EC) via centralised procedure in all EU Member States, based on the European Medicines Agency (EMA) experts' opinion.
| Name | Tecartus |
|---|---|
| Active Substance | autologne T-stanice dobivene iz periferne krvi, odabrane pomoću čestica koje prepoznaju CD4 i CD8, aktivirane protutijelima protiv CD3 i CD28, transducirane retrovirusnim vektorom da bi eksprimirale CD28/CD3-zeta kimerični antigenski receptor protiv CD19 i uzgojene u kulturi (breksukaptagen autoleucel) |
| Prescription | Medicinal product subject to medical prescription |
| Type of prescription | ograničeni recept |
| Distribution | Supply through pharmacies (community) |
| ATC Code | L01XL06 |
| Summary of product characteristics (SmPC), labelling and package leaflet (PL) | download |
| Link to the European Medicines Agency's (EMA) product information | download |
| Link to the European Commission's (EC) decisions | download |
